Cervarix® vaccination against HPV lasts at least six years
Source: professional.cancerconsultants.com Author: staff Researchers affiliated with the GlaxoSmithKline Vaccine HPV-007 Study Group have reported that Cervarix® [human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine] has âhigh and sustained immunogenicity, and a favorable safetyâ profile for up to 6.4 years following administration. The details of this study appeared in an early online publication in the Lancet on December 3, 2009.[1] Cervarix [...]